Cover Image
市場調查報告書

缺血性腦中風的開發中產品分析

Ischemic Stroke - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 253642
出版日期 內容資訊 英文 277 Pages
訂單完成後即時交付
價格
Back to Top
缺血性腦中風的開發中產品分析 Ischemic Stroke - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 277 Pages
簡介

所謂缺血性腦中風是指腦部部位血液循環突然停止,造成神經機能受損的疾病。主要的症狀有眼花及暈眩、視野狹窄、顏面鬆弛(麻痺)、失語症、意識水準突然低落等。主要的治療方法有給予抗凝血劑讓造成缺血的血塊溶解,或是透過藥劑療法除去、控制腦腫脹等。

本報告提供全球治療各國的缺血性腦中風用的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

缺血性腦中風概要

治療藥的開發

  • 缺血性腦中風開發中產品:概要
  • 缺血性腦中風開發中產品:比較分析

各企業開發中的缺血性腦中風治療藥

大學/研究機關研究中的缺血性腦中風治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

缺血性腦中風治療藥:開發中的產品一覽(各企業)

缺血性腦中風治療藥:研究中的產品一覽(大學/研究機關別)

缺血性腦中風治療藥的開發企業

  • BioTime, Inc.
  • Athersys, Inc.
  • GlaxoSmithKline plc
  • 第一三共
  • Merck & Co., Inc.
  • FibroGen, Inc.
  • Panacea Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • 三菱田邊製藥
  • Celgene Corporation
  • Neuralstem, Inc.
  • Mesoblast Limited
  • Torrent Pharmaceuticals Limited
  • Pluristem Therapeutics Inc.
  • Huons Co., Ltd.
  • NeuroVive Pharmaceutical AB
  • Digna Biotech, S.L.
  • AGY Therapeutics, Inc.
  • Angion Biomedica Corp.
  • Concert Pharmaceuticals, Inc.
  • Virogenomics, Inc.
  • Stemedica Cell Technologies, Inc.
  • Shin Poong Pharm Co., Ltd.
  • Tarix Pharmaceuticals LTD.
  • International Biotechnology Center Generium
  • MediaPharma s.r.l.

缺血性腦中風:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • vorapaxar sulfate
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • prasugrel hydrochloride
  • GSK-249320
  • MultiStem
  • cenplacel-L
  • levomilnacipran ER
  • dalfampridine ER
  • dextran 40
  • Mesenchymal Bone Marrow Cells
  • filgrastim
  • HU-010
  • Pinocembrin
  • Autologous Bone Marrow Derived Mesenchymal Stem Cells
  • NSI-566
  • Autologous Bone Marrow Derived CD34+ Stem Cells
  • SP-8203
  • FG-4539
  • PAN-811
  • BB-3
  • TXA-127
  • CEP-41750
  • PLX Cells for Ischemic Stroke
  • NVP-014
  • Small Molecules to Inhibit AGY-221 for Ischemic Stroke
  • TRC-051384
  • GNR-014
  • Apotransferrin
  • Stroke Therapy
  • T-33
  • Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure
  • Stem Cell Therapy for Ischemic Stroke
  • AB-144
  • Monoclonal Antibodies to Inhibit tPA for Ischemic Stroke
  • Small Molecule To Inhibit Sodium and hERG Channel For Ischemic Stroke
  • Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction
  • Allogenic Mesenchymal Precursor Cells for Parkinson Disease and Stroke
  • CNB-001
  • meclizine hydrochloride
  • StromAb
  • SMTP-7
  • Small Molecule to Inhibit Sodium Channels for Ischemic Stroke
  • Small Molecules to Inhibit CaMKII for Ischemic Stroke
  • RTL-551
  • DB-017
  • MPHE-001A
  • C-10068
  • Protein for Ischemic Stroke
  • Small Molecules to Inhibit AGY-220 for Ischemic Stroke
  • Small Molecules to Inhibit AGY-218 for Ischemic Stroke
  • Small Molecules to Inhibit AGY-207 for Ischemic Stroke
  • Small Molecule to Inhibit Kinase for Ischemic Stroke
  • Ischemic Stroke Program

缺血性腦中風治療藥:開發中產品的最新趨勢

缺血性腦中風治療藥:開發暫停的產品

缺血性腦中風治療藥:開發中止的產品

缺血性腦中風相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7071IDB

Summary

Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H2 2015', provides an overview of the Ischemic Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ischemic Stroke Overview
  • Therapeutics Development
    • Pipeline Products for Ischemic Stroke - Overview
    • Pipeline Products for Ischemic Stroke - Comparative Analysis
  • Ischemic Stroke - Therapeutics under Development by Companies
  • Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes
  • Ischemic Stroke - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ischemic Stroke - Products under Development by Companies
  • Ischemic Stroke - Products under Investigation by Universities/Institutes
  • Ischemic Stroke - Companies Involved in Therapeutics Development
    • AB Science SA
    • Acticor Biotech
    • advanceCor GmbH
    • Angion Biomedica Corp.
    • AstraZeneca Plc
    • Athersys, Inc.
    • biOasis Technologies Inc.
    • Biogen, Inc.
    • BioTime, Inc.
    • D-Pharm Ltd.
    • Daiichi Sankyo Company, Limited
    • DiaMedica Inc.
    • Digna Biotech, S.L.
    • Genervon Biopharmaceuticals, LLC
    • Glialogix, Inc.
    • Glucox Biotech AB
    • Grifols, S.A.
    • Huons Co., Ltd.
    • International Stem Cell Corporation
    • JN-International Medical Corporation
    • Laboratoires Pierre Fabre SA
    • Lumosa Therapeutics Co., Ltd.
    • MediaPharma s.r.l.
    • Mitsubishi Tanabe Pharma Corporation
    • Neuralstem, Inc.
    • Neurotec Pharma SL
    • NeuroVive Pharmaceutical AB
    • NoNO, Inc.
    • Panacea Pharmaceuticals, Inc.
    • Pharmicell Co., Ltd.
    • PhytoHealth Corporation
    • Remedy Pharmaceuticals, Inc.
    • ReNeuron Group Plc
    • SanBio, Inc.
    • Saneron CCEL Therapeutics, Inc.
    • Simcere Pharmaceutical Group
    • Stemedica Cell Technologies, Inc.
    • SynZyme Technologies, LLC
    • The International Biotechnology Center (IBC) Generium
    • TikoMed AB
    • vasopharm GmbH
    • Vicore Pharma AB
    • Virogenomics, Inc.
  • Ischemic Stroke - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
    • ACT-017 - Drug Profile
    • alteplase biosimilar - Drug Profile
    • BB-3 - Drug Profile
    • BSc-2118 - Drug Profile
    • C-21 - Drug Profile
    • Cerecellgram-Stroke - Drug Profile
    • CNB-001 - Drug Profile
    • DB-017 - Drug Profile
    • DM-199 - Drug Profile
    • Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile
    • DS-1040 - Drug Profile
    • GLX-1112 - Drug Profile
    • glyburide - Drug Profile
    • GM-602 - Drug Profile
    • GXNPC-1 - Drug Profile
    • HBN-1 - Drug Profile
    • HU-010 - Drug Profile
    • Human Plasmin - Drug Profile
    • Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
    • ISC-hpNSC - Drug Profile
    • levomilnacipran hydrochloride ER - Drug Profile
    • LT-3001 - Drug Profile
    • Lysimab - Drug Profile
    • masitinib - Drug Profile
    • Memantine Nitrone - Drug Profile
    • Mesenchymal Stem Cells - Drug Profile
    • MP-124 - Drug Profile
    • MPHE-001A - Drug Profile
    • MTfp-siRNA - Drug Profile
    • MultiStem - Drug Profile
    • NA-1 - Drug Profile
    • natalizumab - Drug Profile
    • NSI-566 - Drug Profile
    • NTKC-005 - Drug Profile
    • NVP-014 - Drug Profile
    • NVX-208 - Drug Profile
    • PAN-811 - Drug Profile
    • Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
    • PHN-014 - Drug Profile
    • Pinocembrin - Drug Profile
    • Polyglactin 370 for Ischemic Stroke - Drug Profile
    • PR-15 - Drug Profile
    • prasugrel hydrochloride - Drug Profile
    • Protein for Ischemic Stroke - Drug Profile
    • Protein for Ischemic Stroke - Drug Profile
    • Protein for Ischemic Stroke - Drug Profile
    • Recombinant Peptide for Ischemic Stroke - Drug Profile
    • Recombinant Plasmin - Drug Profile
    • Recombinant Protein for Ischemic Cerebral Stroke and Myocardial Ischemia - Drug Profile
    • Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
    • ReN-001 - Drug Profile
    • RTL-551 - Drug Profile
    • SB-623 - Drug Profile
    • SIM-071201 - Drug Profile
    • Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
    • Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile
    • Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
    • Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
    • Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile
    • Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile
    • Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile
    • Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile
    • SMTP-7 - Drug Profile
    • StromAb - Drug Profile
    • T-33 - Drug Profile
    • TF-0023 - Drug Profile
    • THR-18 - Drug Profile
    • ticagrelor - Drug Profile
    • TM-700 - Drug Profile
    • TPAi-14 - Drug Profile
    • TPAi-23 - Drug Profile
    • TS-01 - Drug Profile
    • TXA-127 - Drug Profile
    • TXA-302 - Drug Profile
    • UCCB-01144 - Drug Profile
    • Vaccine to Target NMDAR1 for Ischemic Stroke - Drug Profile
    • VACNO - Drug Profile
    • VAS-2870 - Drug Profile
  • Ischemic Stroke - Recent Pipeline Updates
  • Ischemic Stroke - Dormant Projects
  • Ischemic Stroke - Discontinued Products
  • Ischemic Stroke - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ischemic Stroke, H2 2015
  • Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Ischemic Stroke - Pipeline by AB Science SA, H2 2015
  • Ischemic Stroke - Pipeline by Acticor Biotech, H2 2015
  • Ischemic Stroke - Pipeline by advanceCor GmbH, H2 2015
  • Ischemic Stroke - Pipeline by Angion Biomedica Corp., H2 2015
  • Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2015
  • Ischemic Stroke - Pipeline by Athersys, Inc., H2 2015
  • Ischemic Stroke - Pipeline by biOasis Technologies Inc., H2 2015
  • Ischemic Stroke - Pipeline by Biogen, Inc., H2 2015
  • Ischemic Stroke - Pipeline by BioTime, Inc., H2 2015
  • Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2015
  • Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2015
  • Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2015
  • Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
  • Ischemic Stroke - Pipeline by Glialogix, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2015
  • Ischemic Stroke - Pipeline by Grifols, S.A., H2 2015
  • Ischemic Stroke - Pipeline by Huons Co., Ltd., H2 2015
  • Ischemic Stroke - Pipeline by International Stem Cell Corporation, H2 2015
  • Ischemic Stroke - Pipeline by JN-International Medical Corporation, H2 2015
  • Ischemic Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
  • Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2015
  • Ischemic Stroke - Pipeline by MediaPharma s.r.l., H2 2015
  • Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
  • Ischemic Stroke - Pipeline by Neuralstem, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Neurotec Pharma SL, H2 2015
  • Ischemic Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
  • Ischemic Stroke - Pipeline by NoNO, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2015
  • Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2015
  • Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
  • Ischemic Stroke - Pipeline by ReNeuron Group Plc, H2 2015
  • Ischemic Stroke - Pipeline by SanBio, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015
  • Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2015
  • Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
  • Ischemic Stroke - Pipeline by SynZyme Technologies, LLC, H2 2015
  • Ischemic Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
  • Ischemic Stroke - Pipeline by TikoMed AB, H2 2015
  • Ischemic Stroke - Pipeline by vasopharm GmbH, H2 2015
  • Ischemic Stroke - Pipeline by Vicore Pharma AB, H2 2015
  • Ischemic Stroke - Pipeline by Virogenomics, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2015
  • Ischemic Stroke - Dormant Projects, H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..1), H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..2), H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..3), H2 2015
  • Ischemic Stroke - Dormant Projects (Contd..4), H2 2015
  • Ischemic Stroke - Discontinued Products, H2 2015
  • Ischemic Stroke - Discontinued Products (Contd..1), H2 2015
  • Ischemic Stroke - Discontinued Products (Contd..2), H2 2015

List of Figures

  • Number of Products under Development for Ischemic Stroke, H2 2015
  • Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top